IDT Biologika will manufacture five E. coli Master Cell Banks from its Maryland site to support a pentavalent vaccine for the National Institutes of Health (NIH).
The National Institute of Allergy and Infectious Diseases (NIAID), part of the US governmentâ€™s NIH, awarded a 10-year indefinite delivery, indefinite quantity (IDIQ) task order contract to vaccine and drugmaker IDT Biologika.
The task order will support a pentavalent vaccine by manufacturing five Master Cell Banks from IDTâ€™s Rockville, Maryland plant, based on the bacteria E. coli.
JĂĽrgen Betzing, IDTâ€™s CEO, said it is â€śa great honorâ€ť to receive the task order. â€śIDT has a long-standing history and proven track record of developing and manufacturing bacterial and virus-based vaccines. Our state-of-the-art manufacturing facility located in Rockville is well positioned to serve the current task order requirement.â€ť
The contract forms part of a deal inked between the NIH and IDT in October last year, which saw the government agency pay the German drug and vaccine maker an initial $88,900 (â‚¬78,000) to support the first year of the contract. Over 10 years, IDT could receive up to $80 million depending on certain milestones.
Meanwhile, IDT has inaugurated a new multifunctional production facility for vaccines at its site in Dessau-Rosslau, Germany, bringing increased capacity to IDTâ€™s customers.
â€śWe are active in markets that not everyone can serve,â€ť Betzing said last week. â€śThis is only possible when we are able to react flexibly to those marketsâ€™ requirements. This multifunctional production facility provides the basis for doing so.
â€śThe fact that the building has a utilization rate of close to 50 percent right from the start underscores our customersâ€™ high demand and the excellent growth perspectives coming with it.â€ť